Sanofi India Limited
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products.
What Sanofi files
- Others83
- Updates25
- Important18
- Board Meeting11
- Investor Meet9
- Dividend/Bonus6
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI (LODR) Regulations )
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Receipt of Show Cause Notice from GST Authorities
Sanofi India secured a GST refund of ₹1.33 Cr, with the tax authority accepting its request to not adjust it against a ₹0.76 Cr outstanding demand. The company expects no material financial impact.
Sanofi India received a favorable tax order, vacating a demand of ₹0.73 Cr related to TDS on year-end provisions. The company reports no material financial or operational impact from this development.
Sanofi India reported a strong Q2, primarily driven by its diabetes unit, which saw over 14% growth and 17% for the half-year. Total income for the quarter rose 7%, with sales up 6%. Profit Before Tax (PBT) increased 19% to INR 112 Cr from INR 94 Cr, supported by a...